Market Cap 38.38B
Revenue (ttm) 15.41B
Net Income (ttm) 1.37B
EPS (ttm) N/A
PE Ratio 21.41
Forward PE 19.21
Profit Margin 8.91%
Debt to Equity Ratio 2.38
Volume 1,508,600
Avg Vol 1,446,364
Day's Range N/A - N/A
Shares Out 170.30M
Stochastic %K 98%
Beta 1.36
Analysts Strong Sell
Price Target $252.05

Company Profile

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions th...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 919 998 2000
Address:
2400 Ellis Road, Durham, United States
TrendDecoded
TrendDecoded Jan. 5 at 5:20 PM
$AMD $MTB $IQV $HUM $BRO Unfinished correction
0 · Reply
TrendDecoded
TrendDecoded Jan. 5 at 12:48 PM
$SPY $MTB $IQV $HUM $BRO Unfinished correction
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 30 at 5:10 AM
$IQV RSI: 55.89, MACD: 1.5703 Vol: 2.61, MA20: 224.22, MA50: 220.64 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Dec. 29 at 6:24 PM
$IQV just ripped higher — and this move looks earned, not hype. 🚀 IQVIA Holdings shares are up 25.5% in three months, driven by its AWS partnership, a growing R&DS backlog, and buybacks that are lifting its earnings outlook — a powerful combo for confidence. See why retaining IQV stock makes sense right now 👉 https://www.zacks.com/stock/news/2809908/heres-why-you-should-retain-iqv-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2809908-teaser-26674&ADID=SYND_STOCKTWITS_TWEET_2_2809908_TEASER_26674
0 · Reply
ZacksResearch
ZacksResearch Dec. 29 at 5:24 PM
$IQV: Is this a buy with 25.5% gains over the past three months compared to the industry’s 12.1% rise? 📈 🤝 Partnership with AWS enhances its AI capabilities in life sciences, improving efficiency. 📊 R&DS backlog at $32.4B, with $8.1B set to convert in 12 months, and $2.6B in net new bookings. 💸 $1.03B in share buybacks over nine months ending in 2025 supports EPS growth. IQV carries a Zacks Rank of #3 (Hold) but faces liquidity challenges with a declining current ratio. Discover the full investment picture here 👉 https://www.zacks.com/stock/news/2809908/heres-why-you-should-retain-iqv-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2809908-body-26676&ADID=SYND_STOCKTWITS_TWEET_2_2809908_BODY_26676
0 · Reply
AlgorithmAlphaV3
AlgorithmAlphaV3 Dec. 25 at 5:09 AM
$IQV Downside protection weakens if discipline in balancing growth ambition with capital efficiency, with outcomes shaped by timing and discipline. Uncertainty remains until results confirm narrative.
0 · Reply
topstockalerts
topstockalerts Dec. 24 at 7:31 PM
IQVIA Holdings is entering 2026 with a more constructive and lower-risk outlook, as management expects revenue growth next year to be at least in line with 2025, around 5% reported. Shorter decision cycles and a steadier flow of RFPs point to improving demand visibility, supporting a more predictable environment despite uneven sector growth. The Technology & Analytics Solutions segment is expected to remain resilient, driven by sustained client engagement and continued adoption of analytics and AI tools. Bank of America raised its price target to $260 and reiterated a Buy rating, citing IQVIA’s strong long-term fundamentals and competitive positioning across Phase I–IV services Strategically IQVIA announced a partnership with Amazon Web Services as its preferred cloud provider to enhance its AI-powered clinical trial and healthcare analytics platform. Additional support came from Stifel, which raised its price target and Morgan Stanley which initiated coverage with an Overweight $IQV
0 · Reply
lauren_cooper88
lauren_cooper88 Dec. 12 at 5:47 PM
$IQV Mainz Biomed defending $1.00–$1.01 all day with low ~1.00 high ~1.06 and VWAP ~1.027 tells me this is accumulation, then you add DoctorBox bragging 1,000,000+ users and 10,000,000+ results and I’m not ignoring this coil 🚀
0 · Reply
GoldenStripe
GoldenStripe Dec. 12 at 12:03 AM
$IQV green today
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 4 at 7:15 PM
0 · Reply
Latest News on IQV
IQVIA: Increasingly Indispensable In Drug Development

Dec 11, 2025, 1:56 PM EST - 25 days ago

IQVIA: Increasingly Indispensable In Drug Development


Dr. William G. Kaelin Jr. joins IQVIA Board of Directors

Nov 5, 2025, 4:15 PM EST - 2 months ago

Dr. William G. Kaelin Jr. joins IQVIA Board of Directors


IQVIA Holdings Inc. (IQV) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 1:52 PM EDT - 2 months ago

IQVIA Holdings Inc. (IQV) Q3 2025 Earnings Call Transcript


IQVIA Reports Third-Quarter 2025 Results

Oct 28, 2025, 7:00 AM EDT - 2 months ago

IQVIA Reports Third-Quarter 2025 Results


IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025

Sep 30, 2025, 4:15 PM EDT - 3 months ago

IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025


ILMN Stock vs. IQV Stock

Sep 26, 2025, 9:40 AM EDT - 3 months ago

ILMN Stock vs. IQV Stock

ILMN


IQVIA: A Positive Long-Term Outlook Despite Trump Legislation

Sep 11, 2025, 2:00 AM EDT - 4 months ago

IQVIA: A Positive Long-Term Outlook Despite Trump Legislation


IQVIA names Michael Fedock as financial chief

Sep 2, 2025, 9:41 AM EDT - 4 months ago

IQVIA names Michael Fedock as financial chief


IQVIA Announces CFO Transition in Early 2026

Sep 2, 2025, 9:00 AM EDT - 4 months ago

IQVIA Announces CFO Transition in Early 2026


The Big 3: BLDR, IQV, LOW

Aug 19, 2025, 12:00 PM EDT - 4 months ago

The Big 3: BLDR, IQV, LOW

BLDR LOW


IQVIA: Q2 Earnings Exceeded My Expectations

Jul 22, 2025, 5:40 PM EDT - 5 months ago

IQVIA: Q2 Earnings Exceeded My Expectations


IQVIA Holdings Inc. (IQV) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 2:00 PM EDT - 5 months ago

IQVIA Holdings Inc. (IQV) Q2 2025 Earnings Call Transcript


IQVIA Reports Second-Quarter 2025 Results

Jul 22, 2025, 7:00 AM EDT - 5 months ago

IQVIA Reports Second-Quarter 2025 Results


IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

Jul 1, 2025, 7:00 AM EDT - 6 months ago

IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025


IQVIA Launches New AI Agents for Life Sciences and Healthcare

Jun 11, 2025, 7:00 AM EDT - 7 months ago

IQVIA Launches New AI Agents for Life Sciences and Healthcare


IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?

Jun 10, 2025, 2:23 PM EDT - 7 months ago

IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?


IQVIA Announces Pricing of Senior Notes

Jun 2, 2025, 4:37 PM EDT - 7 months ago

IQVIA Announces Pricing of Senior Notes


IQVIA Announces Offering of Senior Notes

Jun 2, 2025, 8:10 AM EDT - 7 months ago

IQVIA Announces Offering of Senior Notes


IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials

May 16, 2025, 8:00 AM EDT - 8 months ago

IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials


IQVIA: Q1 Earnings Support Steady Optimism

May 9, 2025, 1:48 PM EDT - 8 months ago

IQVIA: Q1 Earnings Support Steady Optimism


IQVIA Holdings Inc. (IQV) Q1 2025 Earnings Call Transcript

May 6, 2025, 3:04 PM EDT - 8 months ago

IQVIA Holdings Inc. (IQV) Q1 2025 Earnings Call Transcript


IQVIA Reports First-Quarter 2025 Results

May 6, 2025, 7:00 AM EDT - 8 months ago

IQVIA Reports First-Quarter 2025 Results


IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

Apr 21, 2025, 4:15 PM EDT - 9 months ago

IQVIA to Announce First-Quarter 2025 Results on May 6, 2025


IQVIA Releases 2024 Sustainability Report

Feb 20, 2025, 10:06 AM EST - 11 months ago

IQVIA Releases 2024 Sustainability Report


IQVIA Holdings Inc. (IQV) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 11:58 AM EST - 11 months ago

IQVIA Holdings Inc. (IQV) Q4 2024 Earnings Call Transcript


TrendDecoded
TrendDecoded Jan. 5 at 5:20 PM
$AMD $MTB $IQV $HUM $BRO Unfinished correction
0 · Reply
TrendDecoded
TrendDecoded Jan. 5 at 12:48 PM
$SPY $MTB $IQV $HUM $BRO Unfinished correction
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 30 at 5:10 AM
$IQV RSI: 55.89, MACD: 1.5703 Vol: 2.61, MA20: 224.22, MA50: 220.64 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Dec. 29 at 6:24 PM
$IQV just ripped higher — and this move looks earned, not hype. 🚀 IQVIA Holdings shares are up 25.5% in three months, driven by its AWS partnership, a growing R&DS backlog, and buybacks that are lifting its earnings outlook — a powerful combo for confidence. See why retaining IQV stock makes sense right now 👉 https://www.zacks.com/stock/news/2809908/heres-why-you-should-retain-iqv-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2809908-teaser-26674&ADID=SYND_STOCKTWITS_TWEET_2_2809908_TEASER_26674
0 · Reply
ZacksResearch
ZacksResearch Dec. 29 at 5:24 PM
$IQV: Is this a buy with 25.5% gains over the past three months compared to the industry’s 12.1% rise? 📈 🤝 Partnership with AWS enhances its AI capabilities in life sciences, improving efficiency. 📊 R&DS backlog at $32.4B, with $8.1B set to convert in 12 months, and $2.6B in net new bookings. 💸 $1.03B in share buybacks over nine months ending in 2025 supports EPS growth. IQV carries a Zacks Rank of #3 (Hold) but faces liquidity challenges with a declining current ratio. Discover the full investment picture here 👉 https://www.zacks.com/stock/news/2809908/heres-why-you-should-retain-iqv-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2809908-body-26676&ADID=SYND_STOCKTWITS_TWEET_2_2809908_BODY_26676
0 · Reply
AlgorithmAlphaV3
AlgorithmAlphaV3 Dec. 25 at 5:09 AM
$IQV Downside protection weakens if discipline in balancing growth ambition with capital efficiency, with outcomes shaped by timing and discipline. Uncertainty remains until results confirm narrative.
0 · Reply
topstockalerts
topstockalerts Dec. 24 at 7:31 PM
IQVIA Holdings is entering 2026 with a more constructive and lower-risk outlook, as management expects revenue growth next year to be at least in line with 2025, around 5% reported. Shorter decision cycles and a steadier flow of RFPs point to improving demand visibility, supporting a more predictable environment despite uneven sector growth. The Technology & Analytics Solutions segment is expected to remain resilient, driven by sustained client engagement and continued adoption of analytics and AI tools. Bank of America raised its price target to $260 and reiterated a Buy rating, citing IQVIA’s strong long-term fundamentals and competitive positioning across Phase I–IV services Strategically IQVIA announced a partnership with Amazon Web Services as its preferred cloud provider to enhance its AI-powered clinical trial and healthcare analytics platform. Additional support came from Stifel, which raised its price target and Morgan Stanley which initiated coverage with an Overweight $IQV
0 · Reply
lauren_cooper88
lauren_cooper88 Dec. 12 at 5:47 PM
$IQV Mainz Biomed defending $1.00–$1.01 all day with low ~1.00 high ~1.06 and VWAP ~1.027 tells me this is accumulation, then you add DoctorBox bragging 1,000,000+ users and 10,000,000+ results and I’m not ignoring this coil 🚀
0 · Reply
GoldenStripe
GoldenStripe Dec. 12 at 12:03 AM
$IQV green today
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 4 at 7:15 PM
0 · Reply
RonIsWrong
RonIsWrong Dec. 4 at 7:09 PM
$VKTX $MEDP $IQV $XBI Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics Biotech stocks, including Viking Therapeutics (VKTX), jumped Thursday on a report that the Food and Drug Administration will soon require just one pivotal study to clinch approval for new medical products. The news could give drug and device approvals a boost, but hurt clinical research organizations like Medpace Holdings (MEDP) and Iqvia Holdings (IQV). The companies are responsible for organizing and running the clinical studies necessary to win regulatory approvals. https://www.investors.com/news/technology/medical-stocks-biotech-stocks-research-stocks-fda-clinical-trials/?mod=IBD_FV
0 · Reply
SharePlanner
SharePlanner Dec. 3 at 6:06 PM
Iqvia $IQV doing a great job of holding key support levels on the retest. Strong bounce following a test, hold and bounce off of price level support yesterday. Strong potential for a move back to the upper channel band.
0 · Reply
Estimize
Estimize Dec. 3 at 1:09 PM
Wall St is expecting 3.39 EPS for $IQV Q4 [Reporting 02/18 BMO] http://www.estimize.com/intro/iqv?chart=historical&metric_name=eps&utm_cont
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 5:44 PM
Morgan Stanley has adjusted their stance on IQVIA Hldgs ( $IQV ), setting the rating to Overweight with a target price of 250 → 265.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 1 at 10:47 PM
$IQV Current Stock Price: $228.61 Contracts to trade: $230 IQV Dec 19 2025 Call Entry: $3.70 Exit: $5.94 ROI: 60% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 28 at 7:43 PM
$IQV Share Price: $230.83 Contract Selected: May 15, 2026 $230 Calls Buy Zone: $18.61 – $23.00 Target Zone: $32.90 – $40.21 Potential Upside: 67% ROI Time to Expiration: 167 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 25 at 8:41 PM
$IQV Share Price: $232.34 Contract Selected: May 15, 2026 $230 Calls Buy Zone: $19.89 – $24.57 Target Zone: $36.32 – $44.39 Potential Upside: 72% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Joshua_X
Joshua_X Nov. 25 at 1:31 PM
Life Science Tools — Early Stabilization? Post: Some signs of stabilization in R&D spending. $IQV and $WAT showing relative strength. Keeping $PACB on watch for long-term innovation. Any other life-science names on your radar?
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 22 at 9:13 PM
0 · Reply
RunnerSignals
RunnerSignals Nov. 13 at 9:27 PM
sideways no more $CLBT $BWEN $VGZ $ORLA $IQV all snapped out of their sleepy ranges and popped above their short term averages today
0 · Reply
StockConsultant
StockConsultant Nov. 13 at 2:47 PM
$IQV IQVIA stock, watch for a top of range breakout at https://stockconsultant.com/?IQV
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 10:44 AM
BMO Capital has updated their rating for IQVIA Hldgs ( $IQV ) to Outperform with a price target of 260.
0 · Reply